Mar 28, 2022 Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
Jan 25, 2022 Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference
Jan 25, 2022 Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
Dec 08, 2021 Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer
Sep 22, 2021 Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Jul 08, 2021 Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
May 12, 2021 Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma